Clinical Significance of the Thioredoxin System and Thioredoxin-Domain-Containing Protein Family in Hepatocellular Carcinoma

Dig Dis Sci. 2019 Jan;64(1):123-136. doi: 10.1007/s10620-018-5307-x. Epub 2018 Oct 4.

Abstract

Background: Oxidative stress occurs due to the excessive generation of cellular reactive oxygen species and antioxidant system dysfunction. The thioredoxin (TXN) system and TXN-domain-containing protein (TXNDC) family form networks maintaining the cellular reducing environment. Recently, the importance of these genes in the tumor environment has been emphasized.

Aim: To investigate the clinical significance of TXNs and TXNDC family members in HCC.

Methods: Genomic data from 367 hepatocellular carcinoma (HCC) patients who underwent hepatic resections were analyzed to determine genetic alterations in mRNA and protein levels between patients and healthy controls. In addition, functional enrichment and survival analyses were performed.

Results: HCC patients were shown to have enhanced expression of TXN, TXNRD1, and TXNDC7/9/14 mRNA and protein compared with controls. In accordance with the survival analyses, strong associations were found that patients with TXN, TXNRD1, and TXNDC1/7/9 alterations were proven to have poor prognosis in overall survival. Moreover, gene set enrichment analysis and network analyses revealed that positive correlations were found in mRNA expression of TXN, TXNRD1, and TXNDC7/9 genes with upregulation of the tumor-promoting genes, specifically mTORC1, E2F targets, and Myc targets. On the other hand, elevated expressions of TXNIP and TXNDC11 genes were correlated with suppression of the above tumor-promoting genes.

Conclusions: TXN system and TXNDC family gene panel obtained from the resected tissue of the HCC patients could be used to predict survival prognosis of HCC, and these genes could be considered as potential therapeutic targets for improving HCC survival.

Keywords: Hepatocellular carcinoma; Overall survival; TXN-domain-containing protein; Thioredoxin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / therapy
  • Carrier Proteins / genetics
  • Case-Control Studies
  • Female
  • Gene Expression Regulation, Neoplastic
  • Gene Regulatory Networks
  • Humans
  • Liver Neoplasms / genetics*
  • Liver Neoplasms / mortality
  • Liver Neoplasms / pathology
  • Liver Neoplasms / therapy
  • Male
  • Membrane Proteins / genetics
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Signal Transduction
  • Thioredoxin Reductase 1 / genetics
  • Thioredoxins / genetics*
  • Time Factors

Substances

  • Biomarkers, Tumor
  • Carrier Proteins
  • Membrane Proteins
  • TMX2 protein, human
  • TXN protein, human
  • TXNDC11 protein, human
  • TXNIP protein, human
  • Thioredoxins
  • TXNRD1 protein, human
  • Thioredoxin Reductase 1